Complement-mediated microvascular injury and thrombosis in the pathogenesis of severe COVID-19: A review

Table 1 Randomized clinical trials investigating complement inhibitors in the treatment of coronavirus disease 2019

NCT number	Drug	Mechanism of action	Status	Sponsor
NCT04395456	AMY-101	C3 inhibitor	Not yet recruiting	Amyndas Pharmaceuticals S.A.
NCT04402060	APL-9	C3 inhibitor	Completed	Apellis Pharmaceuticals, Inc.
NCT04346797	Eculizumab	C5 inhibitor	Recruiting	Assistance Publique- Hôpitaux de Paris
NCT04355494	Eculizumab	C5 inhibitor	Expanded access no longer available	Alexion Pharmaceuticals
NCT04288713	Eculizumab	C5 inhibitor	Expanded access available	Hudson Medical
NCT04351503	Eculizumab	C5 inhibitor	Recruiting	University Hospital, Basel, Switzerland
NCT04369469	Ravulizumab	C5 inhibitor	Terminated (Met futility bar at interim analysis)	Alexion Pharmaceuticals
NCT04382755	Zilucoplan (RA101495)	C5 inhibitor	Completed	University Hospital, Ghent
NCT04371367	Avdoralimab	Anti-C5aR	Completed	Assistance Publique Hopitaux De; Marseille &Innate Pharma
NCT04414631	Conestat alfa	C1 esterase inhibitors	Terminated	University Hospital, Basel, Switzerland & Pharming Technologies B.V.
NCT04530136	Ruconest	C1 esterase inhibitors	Recruiting	Pharming Technologies B.V.
NCT04333420	Vilobelimab (IFX-1)	C5a	Recruiting	InflaRx GmbH
NCT04570397	Ravulizumab	C5 inhibitor	Recruiting	Brigham and Women's Hospital
NCT04390464	Ravulizumab	C5 inhibitor	Recruiting	Cambridge University Hospitals NHS; Foundation Trust; Frances Hall